Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma

Re-irradiation is the most common clinical treatment for recurrent nasopharyngeal carcinoma; however, it is associated with severe complications which seriously affect patients' quality of life. Exploring deferred salvage radiotherapy until nasopharyngeal or cervical progression after PD 1 plus GP chemotherapy and immunotherapy maintenance is of great significance for improving the long-term survival and quality of life of patients with unresectable locally recurrent NPC. Thus, the investigators plan to conduct a multicenter, prospective, single-arm phase II clinical trial to evaluate the efficacy and safety of maintenance Immunotherapy with deferred salvage radiotherapy with an objective response to chemoimmunotherapy in patients with unresectable locally recurrent NPC .

NCT Number	NCT07528183
Lead Sponsor	Sun Yat-sen University
Conditions	Nasopharyngeal Cancinoma (NPC)
Enrollment	62 participants
Start Date	2026-07-22
Primary Completion	2032-07-22 (estimated)
Study Completion	2034-07-22 (estimated)
Updated on ClinicalTrials.gov	2026-07-23